BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

611 related articles for article (PubMed ID: 33047272)

  • 21. ZEB1 induced-upregulation of long noncoding RNA ZEB1-AS1 facilitates the progression of triple negative breast cancer by binding with ELAVL1 to maintain the stability of ZEB1 mRNA.
    Luo N; Zhang K; Li X; Hu Y
    J Cell Biochem; 2020 Oct; 121(10):4176-4187. PubMed ID: 31922280
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD155 contributes to the mesenchymal phenotype of triple-negative breast cancer.
    Zheng Q; Gao J; Yin P; Wang W; Wang B; Li Y; Zhao C
    Cancer Sci; 2020 Feb; 111(2):383-394. PubMed ID: 31830330
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long non‑coding RNA FOXD2‑AS1/miR‑150‑5p/PFN2 axis regulates breast cancer malignancy and tumorigenesis.
    Jiang M; Qiu N; Xia H; Liang H; Li H; Ao X
    Int J Oncol; 2019 Mar; 54(3):1043-1052. PubMed ID: 30628646
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extracellular matrix marker LAMC2 targets ZEB1 to promote TNBC malignancy via up-regulating CD44/STAT3 signaling pathway.
    Wang D; Keyoumu K; Yu R; Wen D; Jiang H; Liu X; Di X; Zhang S
    Mol Med; 2024 May; 30(1):61. PubMed ID: 38760717
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Isochlorogenic Acid C Reverses Epithelial-Mesenchymal Transition
    Yu JK; Yue CH; Pan YR; Chiu YW; Liu JY; Lin KI; Lee CJ
    Anticancer Res; 2018 Apr; 38(4):2127-2135. PubMed ID: 29599331
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long non-coding RNA ZEB2-AS1 promotes the proliferation, metastasis and epithelial mesenchymal transition in triple-negative breast cancer by epigenetically activating ZEB2.
    Zhang G; Li H; Sun R; Li P; Yang Z; Liu Y; Wang Z; Yang Y; Yin C
    J Cell Mol Med; 2019 May; 23(5):3271-3279. PubMed ID: 30825262
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TLR5: A prognostic and monitoring indicator for triple-negative breast cancer.
    Shi D; Zhao S; Jiang W; Zhang C; Liang T; Hou G
    Cell Death Dis; 2019 Dec; 10(12):954. PubMed ID: 31852883
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MiR-1976 knockdown promotes epithelial-mesenchymal transition and cancer stem cell properties inducing triple-negative breast cancer metastasis.
    Wang J; Li M; Han X; Wang H; Wang X; Ma G; Xia T; Wang S
    Cell Death Dis; 2020 Jul; 11(7):500. PubMed ID: 32620748
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Receptor-interacting protein kinase 2 promotes triple-negative breast cancer cell migration and invasion via activation of nuclear factor-kappaB and c-Jun N-terminal kinase pathways.
    Singel SM; Batten K; Cornelius C; Jia G; Fasciani G; Barron SL; Wright WE; Shay JW
    Breast Cancer Res; 2014 Mar; 16(2):R28. PubMed ID: 24642040
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Triple-negative breast cancer-derived microvesicles transfer microRNA221 to the recipient cells and thereby promote epithelial-to-mesenchymal transition.
    Das K; Paul S; Singh A; Ghosh A; Roy A; Ansari SA; Prasad R; Mukherjee A; Sen P
    J Biol Chem; 2019 Sep; 294(37):13681-13696. PubMed ID: 31341019
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RNA-binding protein MSI2 isoforms expression and regulation in progression of triple-negative breast cancer.
    Li M; Li AQ; Zhou SL; Lv H; Wei P; Yang WT
    J Exp Clin Cancer Res; 2020 May; 39(1):92. PubMed ID: 32448269
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Luteolin suppresses epithelial-mesenchymal transition and migration of triple-negative breast cancer cells by inhibiting YAP/TAZ activity.
    Cao D; Zhu GY; Lu Y; Yang A; Chen D; Huang HJ; Peng SX; Chen LW; Li YW
    Biomed Pharmacother; 2020 Sep; 129():110462. PubMed ID: 32768952
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Myeloid Zinc Finger 1 (MZF1) Maintains the Mesenchymal Phenotype by Down-regulating IGF1R/p38 MAPK/ERα Signaling Pathway in High-level MZF1-expressing TNBC cells.
    Yue CH; Liu JY; Chi CS; Hu CW; Tan KT; Huang FM; Pan YR; Lin KI; Lee CJ
    Anticancer Res; 2019 Aug; 39(8):4149-4164. PubMed ID: 31366500
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Resveratrol Enhances Inhibition Effects of Cisplatin on Cell Migration and Invasion and Tumor Growth in Breast Cancer MDA-MB-231 Cell Models In Vivo and In Vitro.
    Yang MD; Sun Y; Zhou WJ; Xie XZ; Zhou QM; Lu YY; Su SB
    Molecules; 2021 Apr; 26(8):. PubMed ID: 33921192
    [TBL] [Abstract][Full Text] [Related]  

  • 35. miR-124 regulates EMT based on ZEB2 target to inhibit invasion and metastasis in triple-negative breast cancer.
    Ji H; Sang M; Liu F; Ai N; Geng C
    Pathol Res Pract; 2019 Apr; 215(4):697-704. PubMed ID: 30611621
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MiR-508-3p inhibits cell invasion and epithelial-mesenchymal transition by targeting ZEB1 in triple-negative breast cancer.
    Guo SJ; Zeng HX; Huang P; Wang S; Xie CH; Li SJ
    Eur Rev Med Pharmacol Sci; 2018 Oct; 22(19):6379-6385. PubMed ID: 30338806
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long non-coding RNA LRRC75A-AS1 facilitates triple negative breast cancer cell proliferation and invasion via functioning as a ceRNA to modulate BAALC.
    Li S; Wu D; Jia H; Zhang Z
    Cell Death Dis; 2020 Aug; 11(8):643. PubMed ID: 32811810
    [TBL] [Abstract][Full Text] [Related]  

  • 38. miR-17-5p suppresses cell proliferation and invasion by targeting ETV1 in triple-negative breast cancer.
    Li J; Lai Y; Ma J; Liu Y; Bi J; Zhang L; Chen L; Yao C; Lv W; Chang G; Wang S; Ouyang M; Wang W
    BMC Cancer; 2017 Nov; 17(1):745. PubMed ID: 29126392
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells.
    Hamurcu Z; Ashour A; Kahraman N; Ozpolat B
    Oncotarget; 2016 Mar; 7(13):16619-35. PubMed ID: 26918606
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epithelial-mesenchymal transition induced PAI-1 is associated with prognosis of triple-negative breast cancer patients.
    Xu J; Zhang W; Tang L; Chen W; Guan X
    Gene; 2018 Sep; 670():7-14. PubMed ID: 29802992
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.